scispace - formally typeset
M

Mayank Handa

Publications -  34
Citations -  253

Mayank Handa is an academic researcher. The author has contributed to research in topics: Medicine & Drug delivery. The author has an hindex of 4, co-authored 18 publications receiving 68 citations.

Papers
More filters
Book ChapterDOI

Conclusion and Future Prospective of Polymeric Nanoparticles for Cancer Therapy

TL;DR: Exponential use of polymeric nanoparticles for development of chemotherapeutic agents for cancer management has a sophisticated, novel formulation with minimum collateral damage and efficient targeting of therapeutic agents to tumor.
Journal ArticleDOI

Polycaprolactone based nano-carrier for co-administration of moxifloxacin and rutin and its In-vitro evaluation for sepsis

TL;DR: In-vitro cell line studies concluded that PCL loaded NPs of MOX and RT are safer for administration and In-vItro cellular uptake studies have provided a brief on potential of NPs for cellular uptake.
Journal ArticleDOI

Optimization of Surfactant- and Cosurfactant-Aided Pine Oil Nanoemulsions by Isothermal Low-Energy Methods for Anticholinesterase Activity.

TL;DR: In this article, a pine oil-loaded nano-emulsion preparation was done with pine oil as the oily phase and additionally with different ratios of the non-ionic surfactant (Tween 80) and cosurfactant (ethanol) in an aqueous solution using the isothermal low-energy or spontaneous emulsification method.
Journal ArticleDOI

Nanotechnological approaches for targeting amyloid-β aggregation with potential for neurodegenerative disease therapy and diagnosis.

TL;DR: In this paper, the interactions of nanoparticles with amyloid-β aggregates and their theranostic potential are discussed. But, the authors focus on the interaction of the nanoparticles only with aggregates.
Journal ArticleDOI

Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer's disease.

TL;DR: In this paper, the authors highlight the preclinical assessment of nano-emulsions for Alzheimer's disease and discuss the regulatory constraints to their clinical acceptance, highlighting the potential for the delivery of AD therapeutics owing to their capability for brain drug delivery.